Pharmacokinetics and Dialytic Clearance of Isavuconazole during In Vitro and In Vivo Continuous Renal Replacement Therapy

被引：16

作者：

Biagi, M. ^{[1
]}

Butler, D. ^{[1
]}

Tan, X. ^{[1
]}

Qasmieh, S. ^{[1
]}

Tejani, K. ^{[1
]}

Patel, S. ^{[1
,2
]}

Rivosecchi, R. M. ^{[3
]}

Nguyen, M. H. ^{[4
]}

Clancy, C. J. ^{[4
,5
]}

Shields, R. K. ^{[4
,5
]}

Wenzler, E. ^{[1
]}

机构：

[1] Univ Illinois, Coll Pharm, Chicago, IL 60605 USA

[2] Univ Illinois Hosp & Hlth Sci Syst, Dept Surg, Chicago, IL USA

[3] Univ Pittsburgh, Med Ctr, Dept Pharm & Therapeut, Pittsburgh, PA USA

[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA

[5] Univ Pittsburgh, XDR Pathogen Lab, Pittsburgh, PA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 12期

关键词：

isavuconazole; pharmacokinetics; dialysis; renal replacement; CRRT; CVVH; CVVHD; CVVHDF; CONTINUOUS VENOVENOUS HEMOFILTRATION; CRITICALLY-ILL PATIENTS; POPULATION PHARMACOKINETICS; ASPERGILLOSIS; REGIMEN; MODEL;

D O I：

10.1128/AAC.01085-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid-organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated. In vivo, the mean (+/- standard deviation [SD]) plasma PK parameters of isavuconazole were as follows: maximum concentration of drug in serum (C-max), 4.00 +/- 1.45 mg/liter; minimum concentration of drug in serum (C-min), 1.76 +/- 0.76 mg/liter; half-life (t(1/2)), 48.36 +/- 29.78 h; volume of distribution at steady state (V-ss), 288.78 +/- 182.11 liters, clearance at steady state (CLss), 4.85 +/- 3.79 liters/h; and area under the concentration-time curve (AUC), 54.01 +/- 20.98 mg . h/liter. Transmembrane clearance represented just 0.7% of the total isavuconazole clearance. These data suggest that isavuconazole is not readily removed by CRRT and no dose adjustments are necessary.

引用

页数：6

共 28 条

[1] Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach [J].